HYZA, M., P. SILHAN, E. CESKOVA, T. SKRONT, I. KACIROVA, R. URINOVSKA a M. GRUNDMANN. Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis. Neuropsychiatric Disease and Treatment. New Zealand: Dove Medical Press, roč. 17, s. 1069-1075. ISSN 1176-6328. doi:10.2147/NDT.S298050. 2021.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Plasma Levels of Long-Acting Injectable Antipsychotics in Outpatient Care: A Retrospective Analysis
Autoři HYZA, M., P. SILHAN, E. CESKOVA, T. SKRONT, I. KACIROVA, R. URINOVSKA a M. GRUNDMANN.
Vydání Neuropsychiatric Disease and Treatment, New Zealand, Dove Medical Press, 2021, 1176-6328.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Stát vydavatele Česká republika
Utajení není předmětem státního či obchodního tajemství
WWW URL
Impakt faktor Impact factor: 2.154 v roce 2013
Doi http://dx.doi.org/10.2147/NDT.S298050
UT WoS 000641063300001
Klíčová slova anglicky therapeutic drug monitoring; antipsychotics; psychotic disorders; schizophrenia
Štítky Excelence Science, FN OSTRAVA, RIV, user
Změnil Změnila: Bc. Hana Vladíková, BBA, učo 244692. Změněno: 7. 12. 2021 13:00.
Anotace
Purpose: Antipsychotic efficacy in schizophrenia depends on its availability in the body. Although therapeutic outcomes remain still far from satisfactory, therapeutic drug monitoring not a common part of clinical practice during treatment with long-acting injectable antipsychotics (LAI AP). The real effectiveness of LAI AP is thus uncertain. Patients and Methods: We made a retrospective evaluation of plasma levels of LAI AP. Collection of blood samples was performed just before the drug application and one week later. Forty patients with a stabilized clinical condition and steady-state plasma levels were included. Results: In the observed cohort of patients, flupentixol decanoate (n = 23) was the most often used drug, followed by fluphenazine decanoate (n = 7), haloperidol decanoate (n = 5), paliperidone palmitate (n = 3), and risperidone microspheres (n = 2). Just 5 of 40 patients were treated with a monotherapy. In the period before the application, 60% of the patients did not reach the therapeutic reference range (TRR) and 20% of the patients had an undetectable plasma level. At the time of collection of the second blood samples performed after 7 days, 24% of the patients were under the TRR. Conclusion: We have found a surprisingly high incidence of plasma levels under the TRR patients treated with LAI AP. Notwithstanding individual variability in pharmacokinetics, seems that LAI AP may be underdosed in usual clinical practice.
Návaznosti
90128, velká výzkumná infrastrukturaNázev: CZECRIN III
VytisknoutZobrazeno: 20. 4. 2024 03:13